Baxfendy

RSS

Opinion

EMA has issued an opinion on this medicine

baxdrostat
MedicineHumanOpinion

Spanish is available via eTranslation, the European Commission's machine translation service.

Translate to Spanish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Baxfendy, intended for the treatment of insufficiently controlled hypertension.

The applicant for this medicinal product is AstraZeneca AB.

Baxfendy will be available as 1 mg and 2 mg film-coated tablets. The active substance of Baxfendy is baxdrostat, an antihypertensive (ATC code: C02KN02). Baxdrostat is a selective inhibitor of human aldosterone synthase. Aldosterone contributes to hypertension by promoting renal sodium and water retention, which increases blood volume, and by acting directly on the blood vessels to promote dysfunction, inflammation and fibrosis. 

The benefits of Baxfendy are clinically relevant and statistically significant reductions in systolic and diastolic blood pressure in patients with uncontrolled high blood pressure despite the use of at least two blood pressure-lowering medicinal products, as observed in randomised, double‑blind, placebo‑controlled studies.

The most common side effect with baxdrostat is hyperkalaemia.

The full indication is:

Baxfendy is indicated for the treatment of adult patients with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products (see section 5.1).

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Product details

Name of medicine
Baxfendy
Active substance
baxdrostat
International non-proprietary name (INN) or common name
baxdrostat
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C02K
EMA product number
EMEA/H/C/006597
Marketing authorisation applicant
AstraZeneca AB
Opinion adopted
12/11/2026
Opinion status
Positive
This page was last updated on

Share this page